TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Meaningful biomarkers in myeloproliferative neoplasms and Q&A

Featured:

Alessandro M. VannucchiAlessandro M. VannucchiTiziano BarbuiTiziano BarbuiChloé JamesChloé JamesLaura MichaelisLaura MichaelisHaifa Kathrin Al-AliHaifa Kathrin Al-AliSteffen KoschmiederSteffen KoschmiederBenjamin RollesBenjamin Rolles

Aug 6, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.


During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss meaningful biomarkers in myeloproliferative neoplasms (MPN). Benjamin Rolles delivered a presentation on potential biomarkers in MPN and the impact this may have on clinical practice and management strategies.

Meaningful biomarkers in myeloproliferative neoplasms

Benjamin Rolles opens by discussing the biomarkers associated with driving MPN, going on to highlight the need to better understand clonal hematopoiesis, particularly why certain healthy individuals within the population can harbor MPN driver gene mutations but not develop MPNs while others do. Rolles also covers high-risk constellations in MPN as well as biomarkers for disease monitoring. Rolles concluded that there is still a significant need for new and improved biomarkers in MPN in order to optimize treatment monitoring, treatment selection, and predicting adverse events.

Q&A

Following their presentation, Rolles chaired a Q&A session featuring steering committee members Alessandro Vannucchi, Laura Michaelis, Haifa Kathrin Al-Ali, Tiziano Barbui, Steffen Koschmieder, and Chloe James. Discussions include how to assess allele burden frequency in the clinic, the importance of this in diagnosis, and when to measure allelic burden. This Q&A session closes with a discussion on the management strategies for patients with a consistent increase of variant allele frequency.

Meaningful biomarkers in myeloproliferative neoplasms: Q&A session